Glucotrack, Inc. (GCTK) stock
GCTKOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.68−0.04 (-5.56%)
Close on Oct 19, 2026Market cap $3.43MP/E 0.0Yield –
Earnings
Glucotrack's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2025
–
EPS, Q3 FY2025
-$4.64
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Glucotrack's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025after the close | – | – | -$4.64 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025after the close | – | – | -$0.67 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Glucotrack has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Glucotrack puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Glucotrack filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Update
- Results
- to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 MilestonesUpdate
See a number that looks wrong?